Prediction of fat-free mass in children HS Al-Sallami, A Goulding, A Grant, R Taylor, N Holford, SB Duffull Clinical pharmacokinetics 54, 1169-1178, 2015 | 143 | 2015 |
Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol A Mooranian, R Negrulj, N Chen-Tan, HS Al-Sallami, Z Fang, TK Mukkur, ... Drug design, development and therapy, 1221-1230, 2014 | 78 | 2014 |
Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes R Negrulj, A Mooranian, N Chen-Tan, HS Al-Sallami, M Mikov, ... Artificial cells, nanomedicine, and biotechnology 44 (5), 1290-1297, 2016 | 59 | 2016 |
Mammary Gland Pathology Subsequent to Acute Infection with Strong versus Weak Biofilm Forming Staphylococcus aureus Bovine Mastitis Isolates: A Pilot Study … J Gogoi-Tiwari, V Williams, CB Waryah, P Costantino, H Al-Salami, ... PLoS One 12 (1), e0170668, 2017 | 57 | 2017 |
Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study A Mooranian, R Negrulj, N Chen-Tan, HS Al-Sallami, Z Fang, T Mukkur, ... Drug design, development and therapy, 1003-1012, 2014 | 57 | 2014 |
Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes A Mooranian, R Negrulj, HS Al-Sallami, Z Fang, M Mikov, ... Aaps Pharmscitech 16, 45-52, 2015 | 52 | 2015 |
Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study A Mooranian, S Raj Wagle, B Kovacevic, R Takechi, J Mamo, V Lam, ... Scientific Reports 10 (1), 106, 2020 | 50 | 2020 |
Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment A Mooranian, R Negrulj, HS Al-Sallami, Z Fang, M Mikov, ... Journal of microencapsulation 32 (2), 151-156, 2015 | 46 | 2015 |
The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti … A Mooranian, R Negrulj, R Takechi, J Mamo, H Al-Sallami, H Al-Salami Drug delivery and translational research 8, 543-551, 2018 | 44 | 2018 |
Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 … A Mooranian, N Zamani, R Takechi, H Al-Sallami, M Mikov, ... Artificial cells, nanomedicine, and biotechnology 46 (sup3), 748-754, 2018 | 35 | 2018 |
Between-subject variability: should high be the new normal? HS Al-Sallami, SL Cheah, SY Han, J Liew, J Lim, MA Ng, H Solanki, ... European journal of clinical pharmacology 70, 1403-1404, 2014 | 35 | 2014 |
The time course of drug effects HS Al‐Sallami, VV Pavan Kumar, CB Landersdorfer, JB Bulitta, SB Duffull Pharmaceutical Statistics: The Journal of Applied Statistics in the …, 2009 | 30 | 2009 |
A framework for simplification of quantitative systems pharmacology models in clinical pharmacology A Derbalah, H Al‐Sallami, C Hasegawa, A Gulati, SB Duffull British Journal of Clinical Pharmacology 88 (4), 1430-1440, 2022 | 24 | 2022 |
Newborn vitamin K prophylaxis: a historical perspective to understand modern barriers to uptake A Majid, M Blackwell, RS Broadbent, DP Barker, HS Al-Sallami, ... Hospital pediatrics 9 (1), 55-60, 2019 | 24 | 2019 |
Choosing the allometric exponent in covariate model building J Sinha, HS Al-Sallami, SB Duffull Clinical pharmacokinetics 58, 89-100, 2019 | 22 | 2019 |
Dabigatran: rational dose individualisation and monitoring guidance is needed SB Duffull, DFB Wright, HS Al-Sallami, PJ Zufferey, JM Faed The New Zealand Medical Journal (Online) 125 (1357), 2012 | 22 | 2012 |
A review of the methods and associated mathematical models used in the measurement of fat-free mass J Sinha, SB Duffull, HS Al-Sallami Clinical Pharmacokinetics 57, 781-795, 2018 | 21 | 2018 |
Revisiting the pharmacology of unfractionated heparin A Derbalah, S Duffull, F Newall, K Moynihan, H Al-Sallami Clinical Pharmacokinetics 58 (8), 1015-1028, 2019 | 20 | 2019 |
Development of a population pharmacokinetic–pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patients H Al‐Sallami, F Newall, P Monagle, V Ignjatovic, N Cranswick, S Duffull British journal of clinical pharmacology 82 (1), 178-184, 2016 | 19 | 2016 |
The Influence of Dosing Time, Variable Compliance and Circadian Low‐Density Lipoprotein Production on the Effect of Simvastatin: Simulations from a Pharmacokinetic … DFB Wright, VV Pavan Kumar, HS Al‐Sallami, SB Duffull Basic & clinical pharmacology & toxicology 109 (6), 494-498, 2011 | 18 | 2011 |